[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338918-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338918-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","growth-differentiation-factor-15-may-be-a-novel-biomarker-in-pancreatic-cancer-a-review-narrative-review","Growth differentiation factor-15 may be a novel biomarker in pancreatic cancer - A review - Narrative Review","","Pancreatic cancer is a highly malignant and invasive gastrointestinal tumor often detected at an advanced stage, leading to poor prognosis and high mortality. CA199 is the only FDA-approved biomarker for diagnosis but has major limitations. GDF-15 is proposed as a novel biomarker for diagnosis, treatment efficacy prediction, and prognosis evaluation. A literature search in PubMed and Web of Science synthesized mechanisms, characteristics, and clinical value of GDF-15 to support detection and treatment strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/growth-differentiation-factor-15-may-be-a-novel-biomarker-in-pancreatic-cancer-a-review-narrative-review/338918/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/growth-differentiation-factor-15-may-be-a-novel-biomarker-in-pancreatic-cancer-a-review-narrative-review/338918.png","ImageObject",300,407,{"name":42,"@type":43},"Himbo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early detection important in pancreatic cancer?","Question",{"text":63,"@type":64},"Early stages often lack typical symptoms and signs, and the disease has aggressive high malignancy. Earlier detection and treatment are crucial to improve patient outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the limitation of CA199 as a pancreatic cancer biomarker?",{"text":68,"@type":64},"CA199 has low average sensitivity and specificity and a low positive predictive value. It can also produce false-negative results in patients lacking the Lewis antigen.",{"name":70,"@type":61,"acceptedAnswer":71},"How is GDF-15 expected to improve pancreatic cancer evaluation?",{"text":72,"@type":64},"GDF-15 is expected to serve as a biomarker for diagnosis, efficacy prediction, and prognosis assessment, offering clinical value beyond CA199.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338918,1790410889,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":97,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","®  \n Narrative Review   \nGrowth differentiation factor-15 may be a novel biomarker in pancreatic cancer  \nA review  \nMeng Guoa , Hui Zhao, MDa ,*   \n\n| Abstract\u003Cbr>Pancreatic cancer is a highly malignant and invasive gastrointestinal tumor that is often diagnosed at an advanced stage with a poor prognosis and high mortality. Currently, carbohydrate antigen199(CA199) is the only biomarker approved by the FDA for the diagnosis of pancreatic cancer, but it has great limitations. Growth differentiation factor-15 (GDF-15) is expected to bea novel biomarker for the diagnosis, efficacy prediction, and prognosis assessment of pancreatic cancer patients. In this paper, we searched the keywords GDF-15, macrophage inhibitory cytokine-1 (MIC-1), CA199, pancreatic cancer, and tumor markers in PubMed and Web of Science, searched related articles, and read and analyzed the retrieved papers. Finally, we systematically described the characteristics, mechanism of action, and clinical value of GDF-15, aiming to provide help for the detection and treatment of pancreatic cancer. |\n| --- |\n| Abbreviations: AKT = Namely PKB (protein kinase B) , CA199 = carbohydrate antigen199, CREB-1 = cAMP responsive element binding protein 1, ERK = extracellular signal-related kinas, GDF-15 = growth differentiation factor-15, GFRAL = GDNF family receptor α-like, MIC-1 = macrophage inhibitory cytokine-1, NF-kB = nuclear factor kappa B, TGF-β = transforming growth factor-β . |\n| Keywords: CA199 , GDF-15 , MIC-1 , pancreatic cancer, tumor marker |\n\n1. Introduction  \nDue to the lack of typical symptoms and signs in the early stages, as well as its aggressive nature and high malignancy, pancreatic cancer often has a grim prognosis and high mortality rate. It is projected to become the second leading cause of cancer-related deaths by 2030.[1,2] Surgical resection is the most effective method for treating patients with pancreatic cancer at present. However, only a small percentage (15%– 20%) of newly diagnosed patients are eligible for surgery. In comparison, the majority (80%) are diagnosed with either locally advanced or metastatic pancreatic cancer, rendering them ineligible for surgery. These patients often have to resort to palliative treatments such as chemotherapy, radiotherapy, and immunotherapy. Unfortunately, the results and prognosis of these treatments are not favorable. Therefore, early detection and treatment are crucial for improving outcomesin pancreatic cancer patients. [3,4] Due to its universality and rapid imaging characteristics,CT is the first choice for evaluating patients with suspicious conditions. However, CT has a low detection rate for isodense lesions and small masses. On the other hand, MRI has better resolution compared to CT. Nevertheless, MRI has some disadvantages, such as the  \nabsence of standardized parameters for advanced imaging sequences, limited spatial resolution, susceptibility to patient movement and intestinal gas, and challenges for patients with claustrophobia. [5,6] Endoscopic ultrasound has better sensitivity and specificity for detecting pancreatic cancer, and it is more accurate in detecting small lesions (0.5–2 cm) . [7] However, experiments conducted on animal models have shown that changes in molecular markers occur before structural changes are detected by imaging techniques in the pancreas. As a result, more studies have begun to focus on identifying molecular markers. [8]  \nTumor markers are produced and secreted by tumor tissues. A good tumor marker should have high specificity and sensitivity, good predictability, and correlate with the tumor stage. However, it is important to note that no tumor marker possesses 100% sensitivity and 100% specificity.[9] To date, the glycoantigen CA199 is the only biomarker approved by the FDA to diagnose pancreatic cancer. However, it still has many shortcomings in diagnosing pancreatic cancer, including low average sensitivity and specificity for CA199 and a positive predictive ","cbCaicr8JFwT1k6x","https://ap.wps.com/l/cbCaicr8JFwT1k6x","pdf",402959,"English","# Introduction\n## Features of the GDF-15","[{\"question\":\"Why is early detection important in pancreatic cancer?\",\"answer\":\"Early stages often lack typical symptoms and signs, and the disease has aggressive high malignancy. Earlier detection and treatment are crucial to improve patient outcomes.\"},{\"question\":\"What is the limitation of CA199 as a pancreatic cancer biomarker?\",\"answer\":\"CA199 has low average sensitivity and specificity and a low positive predictive value. It can also produce false-negative results in patients lacking the Lewis antigen.\"},{\"question\":\"How is GDF-15 expected to improve pancreatic cancer evaluation?\",\"answer\":\"GDF-15 is expected to serve as a biomarker for diagnosis, efficacy prediction, and prognosis assessment, offering clinical value beyond CA199.\"}]","Growth differentiation factor-15 may be a novel biomarker in pancreatic cancer - A review - Narrative Review | PDF",1790026532,13,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e7d9b0ff541e0cea2860e4c41fa41c5.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9796a2150f35b6fa3a4038395dcd7dab.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ef0905b4eb8465a43f2145e5c4b35cd.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fcbea803bfd3cc870e8269e9898dc37.webp",980,1306]